Type 1 Diabetes
Clinical research activity is centered on Type 1 diabetes, with attention to newly diagnosed Stage 3 disease and the preservation of insulin-producing beta cells in the pancreas.
- Autoimmune diabetes
- Beta-cell preservation
- Newly diagnosed Stage 3 Type 1 diabetes
The sponsor’s work in this area reflects a therapeutic focus on slowing disease progression and addressing the underlying immune-mediated loss of pancreatic function.
Immunomodulation
Research interest includes immune-directed therapy aimed at altering the autoimmune process that drives destruction of pancreatic beta cells in Type 1 diabetes.
- Anti-thymocyte immunoglobulin
- Immune tolerance
- Autoimmune intervention
This therapeutic domain is closely tied to efforts to modulate pathogenic immune activity and support remaining endocrine function.
Endocrinology
The sponsor’s clinical interests extend to endocrine disease with emphasis on maintaining glycemic-related pancreatic function in individuals at an early stage of Type 1 diabetes.
- Pancreatic endocrine function
- Insulin production
- Diabetes progression
Work in this area is directed toward understanding how treatment may influence the course of endocrine decline after diagnosis.
Safety and Tolerability Research
Clinical evaluation also includes safety and tolerability considerations for treatment regimens used in people with recent-onset Type 1 diabetes.
- Treatment tolerability
- Clinical safety assessment
- Early-stage intervention
This area supports the assessment of how immune-based therapies are received in a population with active disease progression.
